Page last updated: 2024-11-04

vorinostat and Cardiac Failure

vorinostat has been researched along with Cardiac Failure in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nagata, S1
Marunouchi, T1
Tanonaka, K1
Wang, D1
Fang, C1
Zong, NC1
Liem, DA1
Cadeiras, M1
Scruggs, SB1
Yu, H1
Kim, AK1
Yang, P1
Deng, M1
Lu, H1
Ping, P1

Other Studies

2 other studies available for vorinostat and Cardiac Failure

ArticleYear
Histone Deacetylase Inhibitor SAHA Treatment Prevents the Development of Heart Failure after Myocardial Infarction via an Induction of Heat-Shock Proteins in Rats.
    Biological & pharmaceutical bulletin, 2019, Mar-01, Volume: 42, Issue:3

    Topics: Animals; Gene Expression Regulation; Heart Failure; Heat-Shock Proteins; Histone Deacetylase Inhibit

2019
Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human.
    Molecular & cellular proteomics : MCP, 2013, Volume: 12, Issue:12

    Topics: Acetylation; Animals; Chromatography, Liquid; Gene Expression Regulation; Heart Failure; Heart Trans

2013